Derma Sciences (DSCI) Terminates Aclerastide Phase 3 for Diabetic Foot Ulcer Healing
Tweet Send to a Friend
Derma Sciences (NASDAQ: DSCI) announces the termination of its Phase 3 clinical trials with aclerastide (DSC127) for diabetic foot ulcer ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
